A once-weekly GLP-1/glucagon dual agonist reduced body weight by up to 9.8% at 76 weeks for adults with type 2 diabetes and ...
A noninvasive neurosurgical procedure that delivers radiation to a specific brain pathway significantly reduced symptoms of ...
Prostaglandin analogs for the treatment of glaucoma may have effects on the cornea that lead to lower IOP measurements, ...
The FDA approved a new indication for mavacamten, extending its approval to include certain pediatric patients with ...
Good news is, is that many patient groups are benefiting from TAVR in specific. Thinking about how the studies have changed, ...
But, you know, as a structural heart disease operator, you know, really over the last decade, I've been witness to TAVR just ...
The management of keratoconus has evolved substantially over 3 decades. While corneal transplantation was historically the ...
The FDA has issued a final rule that would remove references to animal studies in its drug safety regulations, as part of a ...
Tavapadon, a treatment for Parkinson’s disease recently approved by the FDA, provides a novel option for healthcare providers ...
Addition of a “simple” clinical risk score on top of current risk assessment tools may improve identification of patients ...
In part one of the SPECTRA clinical trial, 4D-150, an intravitreal gene therapy, demonstrated positive safety outcomes as ...
As much progress as we've made, there are still many unmet needs, and we truly do have a long way to go. But first and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results